Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Chief Financial Officer | December 10, 2021 | December 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OnKure Therapeutics, Inc.
Report date December 10, 2021 · Filed December 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,600 |
Reported balance
After 2021-12-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-12-10 · Grant · Acquired 30,000 · Balance 36,600 F1: Represents a restricted stock unit award. F2: Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 8, 2021. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.69 · Expires 2031-12-09 | Direct | 100,000 |
Reported balance
After 2021-12-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-10 · Grant · Acquired 100,000 · Balance 100,000 F3: The shares vest in a series of 48 successive equal monthly installments measured from December 10, 2021, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award.
F2: Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 8, 2021.
F3: The shares vest in a series of 48 successive equal monthly installments measured from December 10, 2021, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2021 Filed Dec 14, 2021 16:32 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001209191-21-069448 · doc4.xml · derivative · entry 2 Jindal Vineet R. · CIK 0001855115 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-09 F3 · derivative.exercise_date: The shares vest in a series of 48 successive equal monthly installments measured from December 10, 2021, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 16:32 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069448 · doc4.xml · nonDerivative · entry 1 Jindal Vineet R. · CIK 0001855115 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,600 F1 · shares: Represents a restricted stock unit award. F2 · balance_after: Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 8, 2021. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 17:54 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 5,000 | $7.44 | $37,176.50 |
DisclosureSEC source: 0001209191-21-053523 · doc4.xml · nonDerivative · entry 1 Jindal Vineet R. · CIK 0001855115 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The weighted average purchase price for the transaction was $7.4353. The shares were purchased at a range of prices between $7.39 and $7.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.